Oslo Universitets Sykehus
Oslo University Hospital (OUH) is Scandinavia’s largest hospital carrying out more than 1.2 million patient treatments each year and is accredited as a Comprehensive Cancer Center (CCC). The hospital hosts one of the largest radiotherapy centers world-wide, with about 6000 new patients receiving state-of-the-art radiotherapy each year at the Radium Hospital in close vicinity to the Institute for Cancer Research. A Proton Therapy centre is under construction at the same location, expected to open in 2024-2025. The Proton centre will also host preclinical proton-therapy research.
The Institute for Cancer Research (ICR) conducts cutting edge cancer research ranging from basic cancer biology to translational and clinical research. It is the leading cancer research institute in Norway and has a strong international standing. ICR is organized in 6 research departments including Department of Radiation Biology (DRB), currently with altogether 25 research groups, approx. 390 employees and an annual output of approx. 230 peer reviewed publications. Particularly strong research areas are molecular genetics, cell biology, cancer progression and metastasis biology, biomarker discovery and development, radiation biology, tumour immunology/immunotherapy and systems biology. ICR also hosts a department for core facilities including NGS/genomics platforms, bioinformatics, flow- and mass cytometry, pre-clinical imaging scanner (incl. animal MRI) and X-ray machine, and electron-, confocal- and high-resolution microscopy.
The mission of Department of Radiation Biology (DRB) is to improve the outcome of cancer treatment by radiation-based strategies. DRB is an interdisciplinary team of approximately 60 employees consisting of physicists, molecular biologists, biochemists, pharmacists, medical doctors and engineers, organized in 4 research groups and 7 project groups. The research at the department is focused on the biological responses to ionizing and non-ionizing radiation. The vision is to develop a biological understanding of the radiation responses on the molecular, cellular and physiological level, and to utilize this knowledge to design new strategies for the treatment of cancer. Our research strategy involves basic, translational and clinical radiobiological research as well as pursuing innovations for improved radioterapeutic outcome.
